Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Researchers Begin Trial of Shigella Vaccine Candidates

by Global Biodefense Staff
February 20, 2013

Shigellosis SampleResearchers have launched an early-stage human clinical trial of two related candidate vaccines to prevent infection with Shigella. Antibiotics are the standard treatment for patients with shigellosis, but drug-resistant strains of the bacterium are becoming more common and the U.S. government is working towards a preventative vaccine. 

The Phase I clinical trial, funded by the National Institute of Allergy and Infectious Diseases (NIAID), will evaluate the live, attenuated vaccines for safety and their ability to induce immune responses among 90 healthy adults ages 18 to 45 years. The trial is being conducted at the Cincinnati Children’s Hospital Medical Center, one of the eight NIAID-funded Vaccine and Treatment Evaluation Units in the United States. 

Known as WRSs2 and WRSs3, both vaccines target Shigella sonnei, one of the bacteria’s four subtypes and the cause of most shigellosis outbreaks.  The candidates have been found to be safe and effective when tested in nonhuman primates, and are based on a precursor vaccine called WRSs1, which was found to be safe in small human trials in the U.S. and Israel. Researchers at the Walter Reed Army Institute of Research (WRAIR) developed all three versions of the vaccine. 

Shigellosis causes an estimated 90 million cases of severe disease each year and 108,000 deaths, most of which occur in the developing world and affect children under 5 years of age. In the United States, 14,000 shigellosis cases are reported annually, with most cases occurring among children ages 1 to 4 years. 

The pathogen is important not only to global public health, but also to military force protection and readiness. The U.S. Department of Agriculture Food Safety Inspection Service (FSIS) this summer implemented routine verification testing for six Shiga toxin producing Escherichia coli (STEC) pathogens. Shiga toxin is the same toxin as is produced by Shigella. The new targets are in addition to long-standing test requirements for serotype E. coli O157:H7 

The U.S. military recently invested in the development of food pathogen tests for the JBAIDS biodetector, including for the target Shigella spp. 

Additional information about the clinical trial is available at ClinicalTrials.gov under the identifier NCT01336699.

Source: NIAID

Tags: E. coliShigellaVaccinesWRAIR

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC